BioPorto Reports 23% Revenue Growth in Q1 2026, Strengthens Focus on NGAL
Event summary
- BioPorto reported a 23% year-over-year revenue increase to DKK 9.4 million in Q1 2026, driven by 33% growth in NGAL revenue.
- The company divested its antibody business to Janel Life Sciences for USD 10.5 million, strengthening its financial position.
- BioPorto submitted a pre-submission package to the FDA for adult urine NGAL, a key regulatory milestone.
- Adjusted EBITDA loss narrowed by 36% to DKK 17.9 million, in line with expectations.
The big picture
BioPorto's Q1 2026 results reflect its strategic pivot toward NGAL-based diagnostics, supported by regulatory tailwinds from KDIGO's updated guidelines. The divestiture of its antibody business and the FDA pre-submission mark critical steps in its path to commercialization. The company's ability to execute on its Forward Strategy will be key to its long-term success in the competitive diagnostics market.
What we're watching
- Regulatory Progress
- The pace at which BioPorto advances its FDA submission for adult urine NGAL will determine its ability to enter the U.S. market.
- Commercial Execution
- Whether BioPorto can sustain its growth in the U.S. RUO market and expand its hospital network to 60+ by year-end.
- Financial Discipline
- How the company manages its cash position and operational costs as it works toward cash flow positivity in 2028.
Related topics